The company
CVRx, Inc.
CVRX · Nasdaq
CVRX stood above a rising 150-day average in 9 of the last 52 weekly readings, and has been out of that trend for the last 28 weeks. It is 74.6% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 28
- Industry in uptrend
- 27% -9 in 4 wk
- Insider buys, 12 months
- $754K
- Insider sales, 12 months
- $1.3M
- Officials’ trades on record
- 0
- Institutions holding
- 86 (-7)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 9 of 52 weeks.
Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Brent BinkowskiCHIEF OPERATING OFFICER | bought | 26,223at $2.91 | 13 Aug 2026filed 13 Aug 2026 |
| Brent BinkowskiCHIEF OPERATING OFFICER | sold | 1,309at $2.55 | 12 Aug 2026filed 13 Aug 2026 |
| Kevin HykesPRES & CEO | sold | 7,763at $7.90 | 2 Mar 2026filed 3 Mar 2026 |
| Jared OasheimCHIEF FINANCIAL OFFICER | sold | 1,744at $7.90 | 2 Mar 2026filed 3 Mar 2026 |
| Paul VerrastroCHIEF MKTG & STRAT OFFICER | sold | 1,284at $7.90 | 2 Mar 2026filed 3 Mar 2026 |
| Robert Allen JohnChief Revenue Officer | sold | 3,964at $7.90 | 2 Mar 2026filed 3 Mar 2026 |
| Philip B. AdamsonChief Medical Officer | sold | 1,262at $7.90 | 2 Mar 2026filed 16 Mar 2026 |
| Mudit K. JainDirector | bought | 46,800at $6.36 | 20 Feb 2026filed 23 Feb 2026 |
| Mudit K. JainDirector | bought | 600at $4.64 | 18 Feb 2026filed 18 Feb 2026 |
| & Johnson10% owner | sold | 6,337at $10.03 | 26 Nov 2025filed 8 Jan 2026 |
| & Johnson10% owner | sold | 16,000at $10.03 | 25 Nov 2025filed 8 Jan 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| JOHNSON & JOHNSONunchanged · filed 6 Aug 2026 | 4,024,861$20.7M | 00.0% |
| NEA Management Company, LLCreduced · filed 14 Aug 2026 | 1,954,440$10.0M | -71,643−3.5% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 1,245,459$6.4M | +218,900+21.3% |
| ROYAL BANK OF CANADAadded · filed 14 Aug 2026 | 1,233,212$6.3M | +526,262+74.4% |
| GSK plcunchanged · filed 13 Aug 2026 | 1,007,583$5.2M | 00.0% |
| VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026 | 910,576$4.7M | -734−0.1% |
| SILVERCREST ASSET MANAGEMENT GROUP LLCadded · filed 14 Aug 2026 | 878,109$4.5M | +306,088+53.5% |
| GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026 | 440,786$2.3M | +13,714+3.2% |
| PFM Health Sciences, LPnew · filed 14 Aug 2026 | 369,572$1.9M | +369,572 |
| STATE STREET CORPadded · filed 7 Aug 2026 | 366,352$1.9M | +15,804+4.5% |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.